Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(1):119–124. doi: 10.1111/j.1349-7006.2003.tb01362.x

A novel carbazole topoisomerase II poison, ER‐37328: potent tumoricidal activity against human solid tumors in vitro and in vivo

Katsuji Nakamura 1,1,✉, Toshimitsu Uenaka 1,1, Takeshi Nagasu 1, Hiroyuki Sugumi 1, Atsumi Yamaguchi 1, Yoshihiko Kotake 1, Toshimi Okada 1, Junichi Kamata 1, Jun Niijima 1, Tomoyoshi Taniguchi 1, Nozomu Koyanagi 1, Hiroshi Yoshino 1, Kyosuke Kitoh 1, Kentaro Yoshimatsu 1
PMCID: PMC11160147  PMID: 12708485

Abstract

We have discovered a novel topoisomerase II (topo II) poison, ER‐37328 (12,13‐dihydro‐5‐[2‐(dimethylamino)ethyl]‐4H‐benzo[c]py‐rimido[5,6,1‐jk]carbazole‐4,6,10(5H, 11H)‐trione hydrochloride), which shows potent tumor regression activity against Colon 38 cancer inoculated s.c. Here, we describe studies on the cell‐killing activity against a panel of human cancer cell lines and the antitumor activity of ER‐37328 against human tumor xenografts. In a cell‐killing assay involving 1‐h drug treatment, ER‐37328 showed more potent cell‐killing activity (50% lethal concentrations (LC50s) ranging from 2.9 to 20 μM) than etoposide (LC50s>60 μM) against a panel of human cancer cell lines. ER‐37328 induced double‐stranded DNA cleavage, an indicator of topo II‐DNA cleavable complex formation, within 1 h in MX‐1 cells, and the extent of cleavage showed a bell‐shaped relationship to drug concentration, with the maximum at 2.5 μM. After removal of the drug (2.5 μM) at 1 h, incubation was continued in drug‐free medium, and the amount of cleaved DNA decreased. However, at 10 μM, which is close to the LC50 against MX‐1 cells, DNA cleavage was not detected immediately after 1‐h treatment, but appeared and increased after drug removal. This result may explain the potent cell‐killing activity of ER37328 in the 1‐h treatment. In vivo, ER‐37328 showed potent tumor regression activity against MX‐1 and NS‐3 tumors. Moreover, ER‐37328 had a different antitumor spectrum from irinotecan or cisplatin against human tumor xenografts. In conclusion, ER‐37328 is a promising topo II poison with strong cell killing activity in vitro and tumor regression activity in vivo, and is a candidate for the clinical treatment of malignant solid tumors. (Cancer Sci 2003; 94: 119–124)

References

  • 1. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pom.be . Cell 1987;50:917–25. [DOI] [PubMed] [Google Scholar]
  • 2. Holm C, Stearns T, Botstein D. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Biol 1989; 9: 159–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Sumner AT. Scanning electron microscopy of mammalian chromosomes from prophase to telophase. Chromosama 1991; 100: 410–8. [DOI] [PubMed] [Google Scholar]
  • 4. Brill SJ, DiNardo S, Voelkel‐Meiman K, Sternglanz R. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ri‐bosomal RNA. Nature 1987; 326: 414–6. [DOI] [PubMed] [Google Scholar]
  • 5. Wu HY, Shyy SH, Wang JC, Liu LF. Transcription generates positively and negatively supercoiled domains in the template. Cell 1988; 53: 433–40. [DOI] [PubMed] [Google Scholar]
  • 6. Tsao YP, Wu HY, Liu LF. Transcription‐driven supercoiling of DNA: direct biochemical evidence from in vitro studies. Cell 1989; 56: 111–8. [DOI] [PubMed] [Google Scholar]
  • 7. Yang L, Wold MS, Li JJ, Kelly TJ, Liu LF. Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro . Proc Natl Acad Sci USA 1987; 84: 950–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Liu LF. DNA topoisomerase poisons as antitumor drugs. Amu Rev Biochem 1989; 58: 351–15. [DOI] [PubMed] [Google Scholar]
  • 9. Pommier Y, Fesen MR, Goldwasser F. Topoisomerase II inhibitors: the epipodophyllotoxins, m‐AMSA, and the ellipticine derivatives. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia : Lippincott‐Raven; 1996. p. 435–61. [Google Scholar]
  • 10. Ross WE, Sullivan DM, Chow KC. Altered function of DNA topoisomerases as a basis for antineoplastic drug action. In: Jr DeVita VT , Hellman S, Rosenberg SA, editors. Important advances in oncology. New York : Lippincott; 1988. p. 65–81. [PubMed] [Google Scholar]
  • 11. Nakamura K, Sugumi H, Yamaguchi A, Uenaka T, Kotake Y, Okada T, Kamata J, Niijima J, Nagasu T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. Antitumor activity of ER‐37328, a novel carbazole topoisomerase II inhibitor. Mol Cancer Ther 2002; 1: 169–75. [PubMed] [Google Scholar]
  • 12. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer‐drug screening. J Natl Cancer Inst 1990; 82: 1107–12. [DOI] [PubMed] [Google Scholar]
  • 13. Gavrieli Y, Sherman Y, Ben‐Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493–501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Okamoto A, Okabe M, Gomi K. Analysis of DNA fragmentation in human uterine cervix carcinoma HeLa S3 cells treated with duocarmycins or other antitumor agents by pulse field gel electrophoresis. Jpn J Cancer Res 1993; 84: 93–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Trask DK, Muller MT. Biochemical characterization of topoisomerase I purified from avian erythrocytes. Nucleic Acids Res 1983; 11: 2779–800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Trask DK, DiDonato JA, Muller MT. Rapid detection and isolation of cova‐lent DNA/protein complexes: application to topoisomerase I and II. EMBO J 1984; 3: 671–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M. Antitumor activity of 7‐ethyl‐10‐[4‐(l‐piperidino)‐l‐piperidino]carbonyloxy‐camptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944–7. [PubMed] [Google Scholar]
  • 18. Colombo T, Broggini M, Torti L, Erba E, ĎIncalci M. Pharmacokinetics of VP16‐213 in Lewis lung carcinoma bearing mice. Cancer Chemother Pharmacol 1982; 7: 127–31. [DOI] [PubMed] [Google Scholar]
  • 19. Potmesil M, Kirschenbaum S, Israel M, Levin M, Khetarpal VK, Silber R. Relationship of adriamycin concentrations to the DNA lesions induced in hy‐poxic and euoxic L1210 cells. Cancer Res 1983; 43: 3528–33. [PubMed] [Google Scholar]
  • 20. Pommier Y, Schwartz RE, Zwelling LA, Kohn KW. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry 1985; 24: 6406–10. [DOI] [PubMed] [Google Scholar]
  • 21. Pierson V, Pierre A, Pommier Y, Gros P. Production of protein‐associated DNA breaks by 10‐[diethylaminopropylamino]‐6‐methyl‐5H‐pyrido‐[3′,4′:4,5]pyrrolo[2,3‐g]isoquinoline in cultured L1210 cells and in isolated nuclei: comparison with other topoisomerase II inhibitors. Cancer Res 1988; 48: 1404–9. [PubMed] [Google Scholar]
  • 22. Poddevin B, Riou JF, Lavelle F, Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP‐60475), a new antitumor agent in early clinical trials. Mol Pharmacol 1993; 44: 767–74. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES